Antibiotic Selection for Recurrent UTI in CKD Stage 3

Introduction to Antibiotic Selection

• The European Urology Association recommends obtaining urine culture and susceptibility testing immediately after three failed courses of cephalexin in a CKD stage 3 patient with UTI, then initiating empiric therapy with a fluoroquinolone (ciprofloxacin 500 mg PO twice daily or levofloxacin 750 mg PO daily) if local resistance is <10%, adjusting based on culture results 1, 2

Clinical Approach

• Obtain urine culture and susceptibility testing before starting new antibiotics to guide targeted therapy, as repeated cephalexin failures strongly suggest resistant organisms 1, 2
• Assess severity of infection to determine if oral outpatient therapy is appropriate versus need for hospitalization and IV antibiotics 1, 2

Empiric Oral Therapy Options

• Ciprofloxacin 500-750 mg PO twice daily for 7 days (if local fluoroquinolone resistance <10%) 1, 2
• Levofloxacin 750 mg PO daily for 5 days (if local fluoroquinolone resistance <10%) 1, 2
• Trimethoprim-sulfamethoxazole 160/800 mg PO twice daily for 14 days (if susceptible) 1, 2

Multidrug-Resistant Organism Suspected

• For third-generation cephalosporin-resistant Enterobacterales (3GCephRE), consider aminoglycosides (gentamicin 5 mg/kg IV daily or amikacin 15 mg/kg IV daily) for short duration if active in vitro 3, 4, 5
• IV fosfomycin as alternative for complicated UTI without septic shock 3, 4, 5
• Consider cotrimoxazole for non-severe complicated UTI if susceptible 3, 4, 5

Carbapenem-Resistant Enterobacterales (CRE) Identified

• Ceftazidime-avibactam 2.5 g IV q8h (requires dose adjustment in CKD stage 3) 7, 5
• Meropenem-vaborbactam 4 g IV q8h (requires dose adjustment in CKD stage 3) 7, 8
• Plazomicin 15 mg/kg IV q12h (aminoglycoside with activity against CRE, requires dose adjustment) 7, 8

Parenteral Therapy

• Ceftriaxone 1-2 g IV daily (higher dose recommended) for severe or complicated pyelonephritis 1, 2
• Piperacillin-tazobactam 2.5-4.5 g IV three times daily for severe or complicated pyelonephritis 1, 2
• Gentamicin 5 mg/kg IV daily (with dose adjustment for CKD) for severe or complicated pyelonephritis 1, 2

Critical Pitfalls to Avoid

• Avoid nitrofurantoin due to peripheral neuritis risk in CKD patients 6
• Avoid tetracyclines due to nephrotoxicity risk in CKD patients 6
• Use aminoglycosides cautiously due to high nephrotoxicity risk, requires therapeutic drug monitoring 6

Resistance Considerations

• Three failed cephalexin courses strongly suggest ESBL-producing organisms or other resistant pathogens 1, 2
• Do not use cephalosporins empirically after documented cephalexin failures without culture confirmation of susceptibility 3, 4
• Local antibiogram data should guide empiric choices, as fluoroquinolone resistance varies significantly by region 1, 2

Antibiotic Stewardship Considerations

• Step down to oral narrow-spectrum therapy once culture results available and patient stabilized 3, 4, 5
• Avoid broad-spectrum agents (new beta-lactam/beta-lactamase inhibitor combinations) for non-MDR organisms to preserve their utility 3, 4, 5
• Shorter treatment durations (5-7 days) are appropriate for uncomplicated pyelonephritis with fluoroquinolones 1, 2